Volume 2,Issue 2
Fall 2024
Bioinformatics Evaluation of the Clinicopathological and Prognostic Significance of PD-L1 Expression in Lung Adenocarcinoma
Objective: To evaluate the clinicopathological and prognostic significance of PD-L1 expression in lung adenocarcinoma using bioinformatics and validate its expression and clinicopathological correlation through immunohistochemistry. Methods: The GEPIA database was utilized to analyze the quantitative expression of PD-L1 mRNA, which was further validated using immunohistochemistry. The impact of PD-L1 expression on the prognostic value of lung adenocarcinoma was assessed using the Kaplan-Meier Plotter. Immune cell infiltration in lung adenocarcinoma was analyzed with Timer 2.0. Additionally, the differential expression of various PD-L1 subtypes in lung adenocarcinoma was examined using the TCGA module of the UALCAN database. Results: Bioinformatics analysis revealed that PD-L1 expression was significantly lower in cancer tissues compared to normal tissues. Immunohistochemistry results demonstrated high expression of PD-L1 in lung adenocarcinoma tissues, whereas low or no expression was observed in adjacent normal tissues. No significant differences in PD-L1 expression were found among different ages, genders, clinical stages, or lymph node metastasis statuses. However, PD-L1 expression was significantly correlated with overall survival and first progression-free survival of patients. Conclusion: The expression of PD-L1 is associated with the survival prognosis of patients with lung adenocarcinoma.
[1] Ni W, Wang X, Wang QS, et al., 2020, Expression and Prognostic Significance of c-Met and GPC1 in Non-Small Cell Lung Cancer. Journal of Practical Oncology, 35(6): 506.
[2] Thompson RH, Gillett MD, Cheville JC, et al., 2005, Costimulatory Molecule B7-H1 in Primary and Metastatic Clear Cell Renal Cell Carcinoma. Cancer, 104(10): 2084.
[3] Konishi J, Yamazaki K, Azuma M, et al., 2004, B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression. Clinical Cancer Research, 10(15): 5094.
[4] Xiao JX, Bai PS, Lai BC, et al., 2005, B7 Molecule mRNA Expression in Colorectal Carcinoma. World Journal of Gastroenterology, 11(36): 5655.
[5] Loos M, Langer R, Schuster T, et al., 2011, Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma. The Annals of Thoracic Surgery, 91(4): 1025.
[6] Dumitru A, Dobrica EC, Croitoru A, et al., 2022, Focus on PD-1/PD-L1 as a Therapeutic Target in Ovarian Cancer. International Journal of Molecular Science, 23(20): 12067.
[7] Yu H, Boyle TA, Zhou CC, et al., 2016, PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 11(7): 964.
[8] Xie WY, He Y, Fu X, et al., 2022, Relationship Between Histological Features Related to Lung Adenocarcinoma and PD-L1 Expression and EGFR Mutation Types. Chinese Journal of Clinical Oncology, 49(15): 769.
[9] Zhou RG, Wang Y, Chen JS, et al., 2022, Relationship Between c-MET, BRAF, ROS1 Gene Mutations and Clinical Features in Non-Small Cell Lung Cancer. Journal of Molecular Diagnostics and Therapy, 14(7): 1129.
[10] Thai AA, Solomon BJ, Sequist LV, et al., 2021, Lung Cancer. Lancet, 398(10299): 535.
[11] Qin WH, Zhang HW, Yang BJ, et al., 2022, Study on the Correlation Between PD-L1 Expression and Clinicopathological Data as Well as Gene Mutations in Patients With NSCLC. Journal of Clinical Psychosomatic Diseases, 28(3): 11.
[12] Yang X, Qi C, Ji M, 2019, PD-L1 Status and Survival in Patients With Lung Cancer. JAMA, 322(8): 783.
[13] Zhu JM, 2022, Correlation Study of LAG-3, FGL1, PD-L1, and CD8-+T Cell Expression in Lung Adenocarcinoma, thesis, Xinjiang Medical University.
[14] Li H, Xu Y, Wan B, et al., 2019, The Clinicopathological and Prognostic Significance of PD-L1 Expression Assessed by Immunohistochemistry in Lung Cancer: A Meta-Analysis of 50 Studies With 11,383 Patients. Translational Lung Cancer Research, 8(4): 429.
[15] Shen X, Zhao B, 2018, Efficacy of PD-1 or PD-L1 Inhibitors and PD-L1 Expression Status in Cancer: Meta-Analysis. BMJ, 362: k3529.
[16] Gafeer MM, Hosny Mohammed K, Ormenisan-Gherasim C, et al., 2018, Diagnostic Utility of PD-L1 Expression in Lung Adenocarcinoma: Immunohistochemistry and RNA in Situ Hybridization. Applied Immunohistochemistry & Molecular Morphology, 26(8): e86.
[17] Zhou SM, Zhu JF, Xu JW, et al., 2022, Anti-Tumor Potential of PD-L1/PD-1 Post-Translational Modifications. Immunology, 167(4): 471.